ReShape Lifesciences, Inc. (RSLS) Q4 2023 Earnings Call

Investor webinar replay

Replay transcript excerpt

Good afternoon, and thank you for joining the Reshape Life Sciences Year-End 2023 Conference Call. I would like to turn the call over to Michael Miller from RX Communications. Good afternoon, and thank you for joining the Year-End 2023 Reshape Life Sciences Earnings Call. I'm pleased to be joined today by Paul Hickey, President and Chief Executive Officer, and Tom Stankovich, Chief Financial Officer. Paul will provide an overview and update on the company's activities, which will include a discussion with Dr. Christine Renfielding, a member of Reshape Scientific Advisory Board. Then Tom will review the financial results for the period. We'll then turn the call back over to Paul for some closing remarks, after which we will open the call to a question and answer session. As a reminder, this conference call, as well as Reshape Life Sciences SEC filings and website, including the information, Investor information section of the website contains forward-looking statements within the meaning of the Private Securities Litigation Reform Act of 1995. Actual results could differ materially from those discussed due to known and unknown risks, uncertainties, and other factors. These and additional risks and uncertainties are described more fully in the company's filings with the Securities and Exchange Commission, including those factors identified as risk factors in the company's most recent annual report on Form 10-K. As an additional reminder, Reshape stock is listed on NASDAQ trading under the symbol RSLS. I'll now turn the call over to Paul Hickey, President and CEO of Reshape Life Sciences. Paul? Thank you, Mike, and thanks to all of you for joining us this afternoon for our year-end 2023 earnings call. After I provide an overview and update on Reshape's activities, we'll...